Search Login Register
Juvenile Xanthogranuloma
Summary
Description:
Benign disorder of infants and children caused by proliferation of HISTIOCYTES, macrophages found in tissues. These histiocytes, usually lipid-laden non-Langerhans cells, form multiple yellow-red nodules most often in the skin, the eye, and sometimes in the viscera. Patients appear to have normal lipid metabolism and are classified as a normolipemic non-Langerhans cell histiocytosis.
Also Known As:
Xanthogranuloma, Juvenile; Juvenile Xanthogranulomas; Juvenile Xanthoma; Juvenile Xanthomas; Nevoxanthoendotheliomas Show All >>
Networked: 75
relevant articles (4 outcomes,
1 trials/studies)
for this Disease
Key Drugs and Agents for Juvenile Xanthogranuloma
Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
-
Cladribine
:
2 outcomes in 3 results
:
FDA 3
Generic
-
Triamcinolone Acetonide (Azmacort)
:
1 outcome in 1 result
:
FDA 135
Generic
-
Dermatofibrosarcoma protuberans
:
1 study in 5 results
: IBA
-
S100 Proteins (S 100 Protein)
:
6 results
: IBA
-
Steroids
:
5 results
: IBA
-
Factor XIIIa
:
4 results
: IBA
-
Antigens
:
4 results
: IBA
-
Muramidase (Lysozyme)
:
3 results
: IBA
-
Cholestanol (Coprostanol)
:
3 results
: IBA
-
Cholesterol
:
3 results
: IBA
Show All >>
Diseases Related to Juvenile Xanthogranuloma
-
Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell)
-
Erdheim-Chester Disease
-
Benign Fibrous Histiocytoma (Dermatofibroma)
-
Malignant Fibrous Histiocytoma
-
Neoplasms (Cancer)
Show All >>
Key Therapies for Juvenile Xanthogranuloma
Efficacy Chart >>
-
X-Ray Therapy
:
1 outcome in 1 result
-
Radiotherapy
:
5 results
-
Drug Therapy (Chemotherapy)
:
5 results
-
Salvage Therapy
:
2 results
-
Curettage
:
2 results
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.